Ash Stevens wins SOCMA Silver Awards

Company: Piramal Pharma Solutions

CEO Steve Munk also joins SOCMA board

Ash Stevens, a US-based contract pharmaceutical manufacturer and developer, received two Silver Awards for the successful continuation of its environmental, health, safety and security (EHS&S) programme sponsored by ChemStewards, an initiative of the Society of Chemical Manufacturers and Affiliates (SOCMA). The award, presented annually by SOCMA, recognised Ash Stevens’ Riverview, Michigan facility for implementing a scheme that successfully reduces the environmental footprint of companies that handle and manufacture chemicals, as well as ensuring compliance with all current environmental health and safety regulations.

‘This is the second consecutive year our plant in Riverview has been honoured by SOCMA,’ said Ash Stevens’ president and ceo Stephen Munk.

‘It is tremendously gratifying to have our commitment to the highest possible standards of environmental safety be honoured by an organisation whose primary purpose is to encourage such programmes.’

Munk has joined SOCMA’s Board of Governors. He was elected to the Board during the organisation’s 89th Annual Membership Meeting in New York.

‘As a long time SOCMA member, I look forward to assisting the Board in ensuring that the mission, policies and strategic direction of the association are aligned with membership needs,’ he said.

SOCMA’s Board of Governors provides strategic direction, maintains fiscal responsibility, and helps management develop business plans to deliver member value.

You may also like

Finance

Piramal Pharma Limited announces results for Q3 and 9M FY26

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Manufacturing

Piramal Pharma Solutionsd demonstrates commitment to excellence with net promoter score

Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages
Manufacturing

Updated MHRA GMP certificates strengthen Piramal’s bioconjugates capabilities at Grangemouth

Certification renewal supports clinical and commercial ADC development and manufacturing
Manufacturing

Piramal Pharma reports Q2 and H1 FY26 results amid CDMO challenges

CDMO growth impacted by inventory destocking while consumer healthcare posts mid-teen growth
Research & Development

Piramal Pharma Solutions formalises partnership with IntoCell

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the field
Regulatory

Piramal Pharma Solutions awards Riverview and Digwal for patient centricity

Two sites recognised for innovative initiatives that put patients first
Subscribe now